Shibata K, Akasaki Y, Tokushige A, Nitta M, Kawasoe S, Kubozono T
Hypertens Res. 2025; .
PMID: 39966607
DOI: 10.1038/s41440-025-02149-4.
Rodriguez-Lescure A, Gallego J, Garcia-Alfonso P, Massuti B, Marquez R, Calvo L
Clin Transl Oncol. 2024; 26(8):1896-1907.
PMID: 38578537
PMC: 11249439.
DOI: 10.1007/s12094-024-03411-w.
Rashidi A, Wanchoo R, Izzedine H
Clin J Am Soc Nephrol. 2022; 18(1):121-123.
PMID: 35977777
PMC: 10101584.
DOI: 10.2215/CJN.05610522.
Liu Y, Hu X, Jiang J, Yang L, Zhou S, Liu P
Oncologist. 2020; 25(5):e833-e842.
PMID: 32250517
PMC: 7216448.
DOI: 10.1634/theoncologist.2019-0391.
Rebersek M, Mesti T, Boc M, Ocvirk J
Radiol Oncol. 2019; 53(1):85-95.
PMID: 30840593
PMC: 6411021.
DOI: 10.2478/raon-2019-0013.
Baroreflex functionality in the eye of diffusion tensor imaging.
Tsai C, Poon Y, Chan J, Chan S
J Physiol. 2018; 597(1):41-55.
PMID: 30325020
PMC: 6312450.
DOI: 10.1113/JP277008.
Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.
Gentzler R, Yentz S, Patel J
Curr Treat Options Oncol. 2013; 14(4):595-609.
PMID: 23990213
DOI: 10.1007/s11864-013-0255-3.
Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).
Shah R, Morganroth J, Shah D
Drug Saf. 2013; 36(5):295-316.
PMID: 23620167
DOI: 10.1007/s40264-013-0047-5.
Leptomeningeal metastases in breast cancer.
Scott B, Kesari S
Am J Cancer Res. 2013; 3(2):117-26.
PMID: 23593536
PMC: 3623833.
Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition.
Sunshine S, Dallabrida S, Durand E, Ismail N, Bazinet L, Birsner A
Proc Natl Acad Sci U S A. 2012; 109(28):11306-11.
PMID: 22733742
PMC: 3396467.
DOI: 10.1073/pnas.1203275109.
VEGF inhibition, hypertension, and renal toxicity.
Hayman S, Leung N, Grande J, Garovic V
Curr Oncol Rep. 2012; 14(4):285-94.
PMID: 22544560
PMC: 3746763.
DOI: 10.1007/s11912-012-0242-z.
Tumor control versus adverse events with targeted anticancer therapies.
Keefe D, Bateman E
Nat Rev Clin Oncol. 2011; 9(2):98-109.
PMID: 22182972
DOI: 10.1038/nrclinonc.2011.192.
Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.
Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S
Target Oncol. 2011; 6(4):253-8.
PMID: 22090260
DOI: 10.1007/s11523-011-0201-x.
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity.
Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J
Oncologist. 2011; 16(9):1325-32.
PMID: 21807768
PMC: 3228164.
DOI: 10.1634/theoncologist.2010-0002.
Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review.
Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A
Oncologist. 2011; 16(4):432-44.
PMID: 21441297
PMC: 3228115.
DOI: 10.1634/theoncologist.2010-0271.
Treatment of bevacizumab-induced hypertension by amlodipine.
Mir O, Coriat R, Ropert S, Cabanes L, Blanchet B, Camps S
Invest New Drugs. 2010; 30(2):702-7.
PMID: 20878444
DOI: 10.1007/s10637-010-9549-5.
Antiangiogenic therapies in early-stage breast cancer.
Derleth C, Mayer I
Clin Breast Cancer. 2010; 10 Suppl 1:E23-31.
PMID: 20587404
PMC: 3471531.
DOI: 10.3816/CBC.2010.s.004.
Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome.
Wick A, Schafer N, Dorner N, Schemmer D, Platten M, Bendszus M
J Neurooncol. 2009; 97(1):157-8.
PMID: 19727565
DOI: 10.1007/s11060-009-0003-5.
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules.
Grothey A, Galanis E
Nat Rev Clin Oncol. 2009; 6(9):507-18.
PMID: 19636328
DOI: 10.1038/nrclinonc.2009.110.
